BrainCells Inc.
This article was originally published in Start Up
Executive Summary
Through a series of licenses, material transfer agreements, and exclusive consulting arrangements with key scientific players, start-up BrainCells believes it has created a formidable CNS drug discovery platform for the identification of small molecules that stimulate neurogenesis, the process by which neural stem cells develop into different lineages of the brain.
You may also be interested in...
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.